Reaction
Metastases To Breast reporting signals
As of the last recalculation, Metastases To Breast appears in 323 FAERS reports alongside 14 co-occurring drug terms. The strongest observed disproportionality signal is RIBOCICLIB (PRR 126.3).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Ribociclib | 52 | 126.3 | 126.6 |
| Anastrozole Tablets | 31 | 102.9 | 103.0 |
| Fulvestrant | 43 | 96.6 | 96.7 |
| Ado-Trastuzumab Emtansine | 9 | 70.7 | 70.8 |
| Anastrozole | 32 | 62.2 | 62.3 |
| Everolimus Tablets | 13 | 52.0 | 52.1 |
| Ifosfamide | 14 | 43.8 | 43.9 |
| Trastuzumab | 36 | 37.9 | 37.9 |
| Pertuzumab | 15 | 37.2 | 37.3 |
| Lapatinib | 8 | 34.0 | 34.1 |
| Erlotinib | 5 | 33.8 | 33.8 |
| Abemaciclib | 10 | 33.2 | 33.3 |
| Erlotinib Hydrochloride | 5 | 26.1 | 26.1 |
| Olaparib | 7 | 22.0 | 22.0 |